NJ SAT scores drop for 3rd year, but participation remains high
Newly released data from the state indicates that the average SAT score in New Jersey has fallen for the third consecutive year, a trend that coincided with the statewide transition to online SAT testing for the first time during the 2023/2024 academic year.
Once a cornerstone of college applications, scores from standardized tests like the SAT are increasingly viewed with less weight by colleges and universities. These institutions are now placing greater emphasis on a comprehensive evaluation of a student's achievements and extracurricular involvement throughout their high school career.
Despite this shift, the latest School Performance Reports from the New Jersey Department of Education reveal that nearly 63% of high school seniors in the 2023-2024 academic year, or in prior years, still opted to take the SAT. This figure represents a slight increase compared to the preceding year.
During the 2023-2024 school year, New Jersey students achieved an average math SAT score of 519 and an average reading/writing score of 530, resulting in a combined average score of approximately 1,049. This represents a decrease from the previous year's average combined score of 1,058. A perfect score on the SAT is a combined 1600, with 800 being the maximum score for each section.
The data consistently shows that students attending magnet schools and specialized public high schools generally attained the highest overall SAT scores. For instance, students at High Technology High School in Monmouth County recorded an impressive average SAT score of 1,512.
Here's a look at districts in Monmouth and Ocean counties:
Math score: 557
Reading and writing score: 563
Combined score: 1,120
Math score: 396
Reading and writing score: 407
Combined score: 803
Math score: 581
Reading and writing score: 588
Combined score: 1,169
Math score: 581
Reading and writing score: 579
Combined score: 1,160
Math score: 556
Reading and writing score: 569
Combined score: 1,125
Math score: 542
Reading and writing score: 555
Combined score: 1,097
Math score: 567
Reading and writing score: 565
Combined score: 1,132
Math score: 594
Reading and writing score: 585
Combined score: 1,179
Math score: 550
Reading and writing score: 575
Combined score: 1,125
Math score: 602
Reading and writing score: 603
Combined score: 1,205
Math score: 469
Reading and writing score: 505
Combined score: 974
Math score: 437
Reading and writing score: 451
Combined score: 888
Math score: 574
Reading and writing score: 581
Combined score: 1,155
Math score: 534
Reading and writing score: 554
Combined score: 1,088
Math score: 569
Reading and writing score: 562
Combined score: 1,131
Math score: 478
Reading and writing score: 477
Combined score: 955
Math score: 749
Reading and writing score: 725
Combined score: 1,474
Math score: 642
Reading and writing score: 670
Combined score: 1,312
Math score: 772
Reading and writing score: 740
Combined score: 1,512
Math score: 666
Reading and writing score: 663
Combined score: 1,329
Math score: 704
Reading and writing score: 694
Combined score: 1,398
Math score: 516
Reading and writing score: 542
Combined score: 1,058
Math score: 528
Reading and writing score: 548
Combined score: 1,076
Math score: 468
Reading and writing score: 503
Combined score: 971
Math score: 517
Reading and writing score: 520
Combined score: 1,037
Math score: 608
Reading and writing score: 601
Combined score: 1,209
Math score: 524
Reading and writing score: 543
Combined score: 1,067
Math score: 547
Reading and writing score: 557
Combined score: 1,104
Math score: 500
Reading and writing score: 509
Combined score: 1,009
Math score: 520
Reading and writing score: 545
Combined score: 1,065
Math score: 507
Reading and writing score: 529
Combined score: 1,036
Math score: 500
Reading and writing score: 528
Combined score: 1,028
Math score: 526
Reading and writing score: 545
Combined score: 1,071
Math score: 530
Reading and writing score: 540
Combined score: 1,070
Math score: 523
Reading and writing score: 537
Combined score: 1,060
Math score: 455
Reading and writing score: 458
Combined score: 913
Math score: 452
Reading and writing score: 460
Combined score: 912
Math score: 512
Reading and writing score: 559
Combined score: 1,071
Math score: 555
Reading and writing score: 571
Combined score: 1,126
Math score: 515
Reading and writing score: 550
Combined score: 1,065
Math score: 539
Reading and writing score: 544
Combined score: 1,083
Math score: 539
Reading and writing score: 554
Combined score: 1,093
Math score: 535
Reading and writing score: 536
Combined score: 1,071
Math score: 541
Reading and writing score: 544
Combined score: 1,085
Math score: 506
Reading and writing score: 533
Combined score: 1,039
This article originally appeared on Asbury Park Press: SAT scores in New Jersey down; 2024 results for Jersey Shore
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, 'Ascletis') announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. About ASC47 ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) ( NCT06427590 ) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity ( NCT06972992 ) is ongoing in the U.S., and the first participants were dosed in May 2025. About the American Diabetes Association (ADA) Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact： Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) [email protected] Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) [email protected] [email protected] View original content: SOURCE Ascletis Pharma Inc.
Yahoo
2 hours ago
- Yahoo
Malaysia's first astrophysicist Mazlan Othman says AI can make students better thinkers if schools adapt
KUALA LUMPUR, June 9 — Malaysia's first astrophysicist, Tan Sri Dr Mazlan Othman, believes artificial intelligence (AI) has the potential to make students better thinkers, but she emphasises that schools must change how they assess students. Rather than expecting students to memorise and regurgitate answers, Mazlan suggests teachers should evaluate how creatively students prompt AI tools. 'The skill is in the questioning — teachers should assess students by the kind of questions they ask AI tools,' she told Malay Mail in a recent interview. 'We are far too focused on asking them to find solutions to equations or problems that we give them. Education must aim to let students think for themselves,' she added. Drawing from her astrophysics career, Mazlan said students should be inspired to explore science through an appreciation of arts and nature. 'For example, the way to attract students to maritime science or the maritime industry is not to teach them how to build boats but to inspire them about the sea,' she explained. Mazlan revealed that her own fascination with the sky and stars stemmed from her childhood love of poetry, long before she delved into the celestial sciences. One poem that remains etched in her memory is 'He Wishes for the Cloths of Heaven' by Irish poet William Butler Yeats, which she described as 'a beautiful and poignant piece that captures the beauty of the sky.' Mazlan's fascination for the sky and stars sprung from her childhood love for poetry, way before she discovered astrophysics. — Picture courtesy of Sutra Foundation Breaking barriers in science Born in Seremban, Mazlan has achieved several firsts. She is Malaysia's first astrophysicist, the first woman to earn a doctorate from the University of Otago in New Zealand, and the first Malaysian to lead the United Nations Office for Outer Space Affairs (UNOOSA) — a role she held twice. Astrophysics, however, was not her initial career plan. As a Colombo Plan scholar, Mazlan was required to return to Malaysia after graduation to work as either a physics teacher or a physicist at a nuclear institute. But she hesitated to specialise in atomic or nuclear physics due to prevailing anti-nuclear sentiments in the scientific community. 'Luckily, I discovered astrophysics in my third year. So, I wrote to the Colombo Plan committee to inform them that I was staying in New Zealand to pursue astrophysics,' she said. After returning to Malaysia in 1981, Mazlan became a lecturer at Universiti Kebangsaan Malaysia (UKM), where she pioneered an astrophysics programme. In 1994, she was appointed an astrophysics professor. Mazlan also spearheaded the establishment of the National Planetarium and became its first director-general. She played a pivotal role in designing Malaysia's first remote-sensing satellite, TiungSAT-1, launched in 2000. From 2002 to 2007, she served as the founding director-general of Malaysia's National Space Agency (Angkasa). Leading the global space agenda Mazlan's tenure as UNOOSA director was marked by notable achievements, including negotiating a global protocol to address near-Earth object collisions, such as asteroid strikes. 'At that time, countries were pushing for a protocol to deal with asteroid strikes because a theory suggested that 65 million years ago, an asteroid strike caused the extinction of dinosaurs,' she said. The protocol gained consensus after three years of debates, though member states did not agree to let the UN Security Council make the final decision in such a scenario. During her time at UNOOSA, Mazlan was jokingly referred to as the first point of contact for aliens due to her office's resources and expertise. Highlighting the space sector's projected growth to nearly US$2 trillion (RM9.2 trillion) by 2035, Mazlan noted that global politics continue to heavily influence space-related decisions, as space dominance remains a strategic advantage in warfare. Between her two terms at UNOOSA, Mazlan led Malaysia's first space exploration mission, culminating in astronaut Datuk Dr Sheikh Muszaphar Shukor Sheikh Mustapha's journey to the International Space Station in October 2007. When asked if Malaysia is ready to send a second astronaut to space, Mazlan said it would be worth considering if the country has something novel to contribute to space exploration.
CNN
2 hours ago
- CNN
New tech reveals never-before-seen details in solar corona
A breakthrough in adaptive optics technology captured the clearest images to date of the sun's corona. The incredible resolution of the new images could provide new insights on some of the mysteries surrounding our star.
